Celularity (NASDAQ:CELU - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Thursday.
Celularity Stock Up 6.3%
Shares of NASDAQ CELU traded up $0.14 during midday trading on Thursday, hitting $2.43. The stock had a trading volume of 43,055 shares, compared to its average volume of 125,669. The business's 50 day moving average is $1.74 and its 200-day moving average is $1.99. Celularity has a 52 week low of $1.00 and a 52 week high of $5.22. The company has a market cap of $58.29 million, a P/E ratio of -0.91 and a beta of 0.61.
Celularity (NASDAQ:CELU - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($1.50) by $0.91. The company had revenue of $18.13 million for the quarter, compared to analysts' expectations of $5.20 million. Celularity had a negative return on equity of 119.53% and a negative net margin of 72.72%.
Hedge Funds Weigh In On Celularity
A number of institutional investors and hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC bought a new position in Celularity in the first quarter valued at about $34,000. Keynote Financial Services LLC lifted its stake in shares of Celularity by 90.1% in the 4th quarter. Keynote Financial Services LLC now owns 25,023 shares of the company's stock worth $52,000 after purchasing an additional 11,863 shares during the period. Biltmore Family Office LLC purchased a new position in shares of Celularity in the fourth quarter worth approximately $73,000. Two Sigma Investments LP bought a new stake in Celularity during the fourth quarter valued at approximately $93,000. Finally, C V Starr & Co. Inc. purchased a new stake in Celularity during the fourth quarter valued at approximately $1,589,000. 19.02% of the stock is currently owned by hedge funds and other institutional investors.
About Celularity
(
Get Free Report)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Read More
Before you consider Celularity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celularity wasn't on the list.
While Celularity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
